Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02617407 · ClinicalTrials.gov registry record · Phase 1
Livionex Oral Microbiome and Dental Plaque Control in HSCT Recipients
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT02617407 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 44 participants.
The verdict
NCT02617407, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
Children undergoing chemotherapy, radiation treatment and Hematopoietic Stem Cell Transplantation (HSCT) have significant difficulties achieving good oral hygiene and dental plaque control. HSCT recipients are at a significant risk for bacteremia and sepsis. Livionex® toothpaste was shown to be effective in reducing dental plaques while containing no additives found in other toothpastes that can cause increased gingival irritation. The investigators hypothesize that improved oral hygiene and better plaque control in pediatric patients receiving chemo/radiation treatment or HSCT may result in reduced oral inflammation, decreased amount of oral bacterial pathogens, and reduced risk of oral-pathogen related systemic bacterial infections. The overall goal of this prospective randomized (2:1) pilot study is to determine whether incorporation of the Livionex® toothpaste in the research regimen could reduce dental plaque.
Interventions
- DRUG Livionex® Dental Gel
- DRUG PreviDent 5000 plus/Tom's of Maine Children's toothpaste
- DEVICE Kolibree Toothbrush
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-07-28 |
| Est. Completion | 2020-01-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02617407
The ClinicalTrials.gov registry entry for NCT02617407 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Livionex® Dental Gel is the first listed.
NCT02617407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02617407 about?
NCT02617407 is a clinical study titled "Livionex Oral Microbiome and Dental Plaque Control in HSCT Recipients". Children undergoing chemotherapy, radiation treatment and Hematopoietic Stem Cell Transplantation (HSCT) have significant difficulties achieving good oral hygiene and dental plaque control. HSCT recipients are at a significant risk for bacteremia and sepsis. Livionex® toothpaste was shown to be effe...
What is the current status of trial NCT02617407?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2016-07-28. Estimated completion is 2020-01-27.
What interventions are being tested in trial NCT02617407?
The interventions under investigation include: Livionex® Dental Gel (DRUG), PreviDent 5000 plus/Tom's of Maine Children's toothpaste (DRUG), Kolibree Toothbrush (DEVICE).
Who is sponsoring clinical trial NCT02617407?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.